• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Weights and Aerobics Firm Up Diabetes Control

Article

CALGARY, Alberta -- Exercise strengthens glycemic control for type 2 diabetes patients whether they walk on a treadmill or pump iron, but combining aerobic and resistance exercise appears to have the greatest benefit.

CALGARY, Alberta, Sept. 18 -- Exercise strengthens glycemic control for type 2 diabetes patients whether they walk on a treadmill or pump iron, but combining aerobic and resistance exercise appears to have the greatest benefit.

In just six months, aerobic exercise reduced glycosylated hemoglobin A1c (HbA1c) levels by 0.43 percentage points and resistance training with weights reduced levels by 0.30 percentage points, reported Ronald J. Sigal, M.D., M.P.H., of the University of Calgary and colleagues in the Sept. 18 issue of Annals of Internal Medicine.

Although these groups improved significantly compared with sedentary controls (P=0.007 and P=0.038), patients who did both aerobic and resistance regimens more than doubled the benefit with a drop in HbA1c of 0.9 percentage points.

Other studies have shown that a similar 1% absolute decrease in HbA1c reduces major cardiovascular events 15% to 20% and microvascular complications of diabetes 37%, Dr. Sigal and colleagues added.

The findings affirm exercise as "probably the best strategy for modulating the mean glucose level," commented William E. Kraus, M.D., of Duke University, and Benjamin D. Levine, M.D., of the University of Texas Southwestern Medical Center in Dallas, in their accompanying editorial.

The results "should stimulate all clinicians to include exercise assessment and counseling into every clinic visit." they added.

Exercise has been well established as important to diabetes treatment, but many issues remain around the best "dose" and type of physical activity for patients.

As a "first pass" at addressing these issues, the researchers randomized 251 sedentary, type 2 diabetes patients ages 39 to 70 to one of three exercise regimens or a waiting list, which served as a control.

The regimens consisted of three 45-minute sessions a week of trainer-supervised exercise-aerobic exercise on a stationary bicycle or a treadmill, resistance exercise on weight machines-or a total of six sessions a week for the group assigned to both aerobic and resistance exercise.

Participants were given a weight-maintenance diet and weight loss was low in all groups (0.3 to 2.6 kg).

After a four week run-in period and 22 weeks on the study, the primary endpoint findings included:

  • A 0.51 percentage point HbA1c reduction in the aerobic exercise group versus controls (P=0.007).
  • A 0.38 percentage point HbA1c reduction in the resistance training group compared with controls (P=0.038).
  • An additional 0.46 percentage point HbA1c reduction in the combined exercise group compared with aerobic training alone (P=0.014).
  • An additional 0.59 percentage point HbA1c reduction in the combined exercise group compared with resistance training alone (P=0.001).

The benefit of exercise was greatest among those with poor glycemic control at baseline (P

The DARE trial was supported by grants from the Canadian Institutes of Health Research and the Canadian Diabetes Association.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
© 2024 MJH Life Sciences

All rights reserved.